ClinicalTrials.gg
Not yet recruitingNCT07950592ABODE NACUpdated Nov 20, 2026

The ABODE Study for Patients Undergoing Neoadjuvant Chemotherapy

An interventional study of App in Breast Cancer and Rehabilitation, Breast Cancer (Early Breast Cancer) and Breast Cancer - Female, sponsored by University Health Network, Toronto. Not yet recruiting at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 67 studies in Breast Neoplasms by University Health Network, Toronto — 19 open to participants now, 23 under way, 1 of them phase 3. Breast Neoplasms · University Health Network, Toronto.

Planned enrollment
6th of 40
200 · median 100
Started
2026
with 2 others
No phase
26 of 67
8 open now
Primary completion
2028-10
later than 18 of 22 live
Registered
67th of 67
by date

Among the 67 studies in Breast Neoplasms by University Health Network, Toronto, this one is the 6th largest by planned enrollment of the 40 interventional ones that give a count, is one of 3 that started in 2026, is one of 26 with no phase, reaches primary completion later than 18 of the 22 other live ones, and was the 67th registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

19 of the 67 studies in Breast Neoplasms by University Health Network, Toronto are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 19 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,575 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Breast Neoplasms by University Health Network, Toronto, or all of them as a file.
02

Study summary

Over 12,000 women in Ontario will be diagnosed with BC this year. The COVID-19 pandemic changed the healthcare system, making it important to have high-quality virtual (online) care. Mobile health, which means getting health services on your phone, has become a common part of healthcare.

A previously developed app will be used in this study to improve the virtual care experience for BC patients that will be undergoing neoadjuvant chemotherapy. With this app, patients can:

  • Get personalized resources that can help them navigate through the stages of their treatment.
  • Access vetted information about their cancer \& treatment from a health library.
  • Receive surveys about their health and well-being.
  • Get mental and social support from an e-coach, who are volunteers trained to help and support patients. The e-coaches will provide information, listen to how participants are feeling, and help participants find information they might need.
  • Connect with a physiotherapist to discuss healthy living and wellness.

Participants will be randomly put into one of two groups: one group will use the app, while the other will continue to get usual care without the app. Participants will have access to the app for 12 months. They will be asked about their experience, how they are feeling, and their health status at several timepoints.

At the end of the study, the two groups will be compared to see how active and engaged participants are in their treatment and see how this changes over 12 months. The study team will also examine how participants are feeling emotionally and their overall quality of life. Health service utilization data and chart review will be used to examine how patients used health services over the course of their treatment. Qualitative interviews will be conducted for some patients about their treatment and experience on the app, using photos that they submit throughout the study.

03

Conditions studied

  • Breast Cancer and Rehabilitation
  • Breast Cancer (Early Breast Cancer)
  • Breast Cancer - Female
  • English Speaking and Reading
  • Adults Over 18

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females (assigned female at birth)*
  • Diagnosed with primary invasive BC and receiving curative intent treatment
  • Must have chemotherapy as their first step in treatment
  • Receiving systemic therapy at UHN
  • Age≥18
  • Access to an electronic device with connection to the internet
  • A valid email address
  • Can communicate in English

Exclusion criteria

Exclusion Criteria:

  • Males (assigned male at birth), as BC surgical treatment options and experiences are different
  • Diagnosed with non-operable breast cancer
  • Stage 4/ (whether determined at diagnosis or during surgery)
  • Those with hearing or visual challenges
  • Should not be enrolled in any other UHN study using an e-Health application
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    Intervention (App)

    App + standard care

    Other: App

  • No intervention
    Control

    Standard care

Interventions

  • OtherApp

    The app is a customized version of an eHealth platform that is already in use in other disease sites at UHN. The app has been approved by UHN as a secure communication method. We have customized the app to function within breast cancer care pathways.

06

What researchers measure

Primary outcomes

  1. Patient Activation Measure 13 (PAM-13)

    A 13-item scale measuring self-reported knowledge, skills and confidence for self-management of one's health and healthcare. Items are rated on a 4-point Likert scale (1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly agree). Higher scores indicate a greater patient activation.

    Time frame: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

Secondary outcomes

  1. Impact of Events Scale - Revised (IES-R)

    A 22-item scale measuring subjective distress as it relates to a specific event, based on intrusion and avoidance. Items are rated on a 5-point scale ranging from 0 ("not at all") to 4 ("extremely"). The IES-R yields a total score (ranging from 0 to 88); higher scores mean worse symptoms.

    Time frame: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

  2. Generalized Anxiety Disorder 7 (GAD-7)

    A 7-item measure of generalized anxiety disorder based on symptoms. The GAD-7 is scored by adding its seven items (each 0-3), producing a total from 0-21. Higher scores indicate higher anxiety.

    Time frame: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

  3. European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire: EORTC QLQ-C30

    A 30-item survey assessing of quality of life in cancer patients. The EORTC Core Questionnaire (QLQ-C30) includes six clearly distinguishable functioning scales that have been thoroughly tested and validated. Raw item averages are transformed into a 0-100 scale, where higher scores indicate better functioning (for function/global scales) or worse symptoms (for symptom scales).

    Time frame: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

  4. European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire Information Module (EORTC-INFO25)

    A 25-item survey to measure the amount of medical information received throughout treatment. This scale uses a 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. High score for functional scale indicate higher satisfaction with provided treatment information.

    Time frame: 9 months post-baseline

  5. European Organisation for Research and Treatment of Cancer - Breast Cancer-Specific Quality of Life Questionnaire (EORTC QLQ-BR42)

    A 42-item survey assessing quality of life specifically for breast cancer patients. The survey includes functional scales (body image, sexual functioning, sexual enjoyment, and future perspective) and single item symptoms scales (systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss). Questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Scores average and transformed to 0-100 scale. A high score for functional scale indicate a high/healthy level of functioning while a high score for single item indicate a high level of symptomatology/problems.

    Time frame: Baseline 3 months post-baseline 3 months post-op 12 months post-baseline

  6. Health Education Impact Questionnaire (heiQ)

    A 40-item scale measuring the intended outcomes of health education and self-management programs. heiQ is a validated, self-reported instrument with 8 domains to comprehensively evaluate patient education program and self-management intervention. Each domain score ranges from 1 to 4; a higher score indicates better outcome.

    Time frame: Baseline 9 months post-baseline

  7. Clinical Evaluation Questionnaire -INS (CEQ-INS)

    A 19-item scale evaluation of patient's experience of cancer care in terms of their receipt of useful and relevant information about cancer, assistance with service navigation, and support from their care team. CEQ-INS is a self-reported instrument with questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Higher scores correlate with higher patient satisfaction with the information and support provided from their care team.

    Time frame: 9 months post-baseline

  8. Health Service Outcomes - Wait Times

    The length of time from referral to procedure or discharge, as recorded in the Wait Times Information System (TIS), which tracks wait times for surgeries, diagnostic imaging (e.g., MRI, CT), and alternate level of care (ALC) in Ontario hospitals.

    Time frame: Until 15 months post-baseline

  9. Health Service Outcomes - Ambulatory Clinical Activity

    Ambulatory clinical activity will be collected from the National Ambulatory Care Reporting System (NACRS).

    Time frame: Until 15 months post-baseline

  10. Health Service Outcomes - Discharge Information

    Discharge information will be collected from the Discharge Abstracting Database (DAD) and used to understand discharge and patient recovery.

    Time frame: Until 15 months post-baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2028, 23 months later.

Of 2,669 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 23 months is below that.

Counting every sponsor, half of 2,779 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2026
First posted
Nov 20, 2026
StartEst.
Nov 2026
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07950592
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Nov 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Nov 20, 2026

Study contacts

Tulin Cil
Contact
tulin.cil@uhn.ca
416-946-4507 ext. 3984
Emma Reel
Contact
emma.reel@uhn.ca
647-202-1028

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion